Multiple binomial logistic regression analysis to predict 30-day mortality.

<p>GCS Glasgow Coma Scale; CCCK = caspase-cleaved cytokeratin; APACHE II = Acute Physiology and Chronic Health Evaluation</p><p>Multiple binomial logistic regression analysis to predict 30-day mortality.</p

Kaplan-Meier curves showing the cumulative proportion of survival patients at 30 days and 6 months according to the presence of 4G/4G vs other genotypes of PAI-1 genetic polymorphism.

<p>Kaplan-Meier curves showing the cumulative proportion of survival patients at 30 days and 6 months according to the presence of 4G/4G vs other genotypes of PAI-1 genetic polymorphism.</p

Comparison of clinical and biochemical characteristics between non-surviving and surviving patients with traumatic brain injury.

<p>Data are shown as median (percentile 25^th-75^th) or number (%); APACHE II = Acute Physiology and Chronic Health Evaluation; aPTT = activated partial thromboplastin time; CCCK = caspase-cleaved cytokeratin; CPP = cerebral perfusion pressure; ICP = intracranial pressure; INR = international normalized ratio; ISS = Injury Severity Score; PaO₂ = pressure of arterial oxygen; FIO₂ = fraction inspired oxygen; PaCO₂ = pressure of arterial carbon dioxide</p><p>Comparison of clinical and biochemical characteristics between non-surviving and surviving patients with traumatic brain injury.</p

Characteristics of severe septic patients according to genotype in the PAI-1 gene.

<p>COPD = chronic obstructive pulmonary disease; PaO₂/FIO₂ = pressure of arterial oxygen/fraction inspired oxygen; INR = International normalized ratio aPTT = Activated partial thromboplastin time; APACHE = Acute Physiology and Chronic Health Evaluation; SOFA = Sepsis-related Organ Failure Assessment.</p><p>Characteristics of severe septic patients according to genotype in the PAI-1 gene.</p

Receiver operating characteristic analysis using serum caspase-cleaved cytokeratin (CCCK)-18 levels as a predictor of mortality at 30 days.

<p>Receiver operating characteristic analysis using serum caspase-cleaved cytokeratin (CCCK)-18 levels as a predictor of mortality at 30 days.</p

Comparison of computer tomography findings between non-surviving and surviving patients with traumatic brain injury.

<p>Comparison of computer tomography findings between non-surviving and surviving patients with traumatic brain injury.</p

Survival curves at 30 days using serum caspase-cleaved cytokeratin (CCCK)-18 levels higher or lower than 201 u/L.

<p>Survival curves at 30 days using serum caspase-cleaved cytokeratin (CCCK)-18 levels higher or lower than 201 u/L.</p

Multiple logistic regression analyses to predict 6-month mortality.

<p>Multiple logistic regression analyses to predict 6-month mortality.</p

Early and late mortality according to genotype in the PAI-1 genetis polymorphis.

<p>Early and late mortality according to genotype in the PAI-1 genetis polymorphis.</p

Correlation of serum caspase-cleaved citokeratin (CCCK)-18 levels with serum levels of TNF-α, interleukin-6, interleukin-10, and lactic acid, and with SOFA and APACHE-II scores.

<p>TNF = tumor necrosis factor; SOFA = Sepsis-related Organ Failure Assessment score<b>;</b> APACHE = Acute Physiology and Chronic Health Evaluation (APACHE)-II score; rho = Spearman’s rank correlation coefficient.</p><p>Correlation of serum caspase-cleaved citokeratin (CCCK)-18 levels with serum levels of TNF-α, interleukin-6, interleukin-10, and lactic acid, and with SOFA and APACHE-II scores.</p